Description
Uroplakin III is located on the urothelial surface membrane of the human renal pelvis, ureter, bladder, and urethra. Uroplakin III [BC17] exhibited greater sensitivity than [AU1] in urothelial transitional cell carcinomas during in-house tests. [BC17] staining was negative in all normal and neoplastic tissues, with the exception of the bladder; hence, it is highly selective to uroepithelial tumors and may serve as a valuable tool for differentiating between bladder, renal, and prostate malignancies. The absence of Uroplakin III expression in bladder tumors correlates with increased grade, muscle-invasive characteristics, and lymphovascular invasion. Uroplakin III [BC17] can be utilized in an antibody panel comprising GATA3, p63, and S100P.
Specifications
| Weight | N/A |
|---|---|
| Dimensions | N/A |
| Intended Use | RUO |
| Species Reactivity | Human |
| Source | Mouse Monoclonal |
| Clone | BC17, Biocare Clone |
| Isotype | IgG1 |
| Antigen | Uroplakin III |
| Localization | Membrane and cytoplasmic |
| Positive Control | Bladder cancer |
